Targeting viral reservoirs: Ability of antiretroviral therapy to stop viral replication

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 49-56

  Maldarelli, Frank ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Active cycles of replication; Drug intensification; HIV infection

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; RNA SEQUENCE; TREATMENT RESPONSE; VIREMIA; VIRION; VIRUS DETECTION; VIRUS GENOME; VIRUS LATENCY; VIRUS REPLICATION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; PATHOGENICITY; PROVIRUS; REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV; HUMANS; PROVIRUSES; VIRUS LATENCY; VIRUS REPLICATION;

EID: 79952989124     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834134ea     Document Type: Article

References (62)

1. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295. (Pubitemid 27495741)
2. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632. (Pubitemid 29513968)
3. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536. (Pubitemid 37259753)
4. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009; 49:377-394.
5. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931-939.
6. Gotte M, Rausch JW, Marchand B, et al.. Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions. Biochim Biophys Acta 2010; 1804:1202-1212.
7. Sarafianos SG, Marchand B, Das K, et al. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009; 385:693-713.
8. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087-5094.
9. Dimitrov DS, Willey RL, Sato H, et al. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993; 67:2182-2190. (Pubitemid 23088394)
10. Sato H, Orenstein J, Dimitrov D, Martin M. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 1992; 186:712-724.
11. Pauza CD, Trivedi P, McKechnie TS, et al. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 1994; 205:470-478. (Pubitemid 24371688)
12. Morlese J, Teo IA, Choi JW, et al. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. AIDS 2003; 17:679-683. (Pubitemid 36521073)
13. McDermott JL, Martini I, Ferrari D, et al. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J Clin Microbiol 2005; 43:5272-5274. (Pubitemid 41484036)
14. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005; 79:5203-5210. (Pubitemid 40464268)
15. Reigadas S, Andreola ML, Wittkop L, et al. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 2010; 65:434-437.
16. Panther LA, Coombs RW, Aung SA, et al. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol 1999; 58:165-173. (Pubitemid 29226860)
17. Pierson TC, Kieffer TL, Ruff CT, et al. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76:4138-4144. (Pubitemid 34250581)
18. Delaugerre C, Charreau I, Braun J, et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS 2010; 24:2391-2395.
19. Brussel A, Mathez D, Broche-Pierre S, et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003; 17:645-652. (Pubitemid 36521070)
20. Bushman F. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. AIDS 2003; 17:749-750. (Pubitemid 36521082)
21. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76:3739-3747. (Pubitemid 34250538)
22. Stevens M, De Clercq E, Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev 2006; 26:595-625. (Pubitemid 44230414)
23. Bannwarth S, Gatignol A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr HIV Res 2005; 3:61-71. (Pubitemid 40081286)
24. Fujii K, Hurley JH, Freed EO. Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1. Nat Rev Microbiol 2007; 5:912-916. (Pubitemid 350131179)
25. Adamson CS, Freed EO. Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol 2007; 55:347-387.
26. Venzke S, Keppler OT. Role of macrophages in HIV infection and persistence. Expert Rev Clin Immunol 2006; 2:613-626. (Pubitemid 44355560)
27. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
28. Speck RR, Flexner C, Tian CJ, Yu XF. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother 2000; 44:1397-1403. (Pubitemid 30228333)
29. Humphrey RW, Ohagen A, Davis DA, et al. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. Antimicrob Agents Chemother 1997; 41:1017-1023. (Pubitemid 27194178)
30. Jardine DK, Tyssen DP, Birch CJ. Effect of protease inhibitors on HIV-1 maturation and infectivity. Antiviral Res 2000; 45:59-68. (Pubitemid 30074193)
31. Pas S, Rossen JW, Schoener D, et al. Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2010; 48:1195-1200.
32. Elbeik T, Alvord WG, Trichavaroj R, et al. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr 2002; 29:330-339. (Pubitemid 34288885)
33. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
34. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
35. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586. (Pubitemid 26097216)
36. Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitivesampling Alu-gag PCR. Methods 2009; 47:254-260.
37. Yu JJ, Wu TL, Liszewski MK, et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 2008; 379:78-86.
38. Torti C, Quiros-Roldan ME, Cologni G, et al. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naive to antiretrovirals. Curr HIV Res 2008; 6:43-48. (Pubitemid 351461020)
39. Koelsch KK, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-419. (Pubitemid 351263423)
40. Ibanez A, Puig T, Elias J, et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13:1045-1049. (Pubitemid 29361394)
41. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-2321. (Pubitemid 350287458)
42. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133. (Pubitemid 47482607)
43. Sedaghat AR, Dinoso JB, Shen L, et al. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A 2008; 105:4832-4837. (Pubitemid 351753832)
44. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884. (Pubitemid 351723493)
45. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54:6-9. (Pubitemid 39028960)
46. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
47. Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105:16725-16730.
48. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80:6441-6457. (Pubitemid 43927447)
49. Persaud D, Pierson T, Ruff C, et al. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000; 105:995-1003. (Pubitemid 30203072)
50. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762-1764. (Pubitemid 46870248)
51. Chun TW, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115:3250-3255. (Pubitemid 41567589)
52. Shiu C, Cunningham CK, Greenough T, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol 2009; 83:9731-9742.
53. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73:9404-9412. (Pubitemid 29487096)
54. Frenkel LM, Wang Y, Learn GH, et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 2003; 77:5721-5730. (Pubitemid 36538965)
55. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219. (Pubitemid 37204311)
56. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
57. Yilmaz A, Verhofstede C, D'Avolio A, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010. [Epub ahead of print]
58. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-919.
59. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
60. Hatano HH, Hayes TL, Dahl V, Sinclair E, Lee T-H, Hoh R, Lampris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (in press).
61. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med Apr 2010; 16:460-465.
62. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24:2451-2460.